In the latest trading session,, 0.73 million Transmedics Group Inc (NASDAQ:TMDX) shares changed hands as the company’s beta touched 2.07. With the company’s most recent per share price at $96.85 changing hands around $5.44 or 5.95% at last look, the market valuation stands at $3.25B. TMDX’s current price is a discount, trading about -83.14% off its 52-week high of $177.37. The share price had its 52-week low at $56.83, which suggests the last value was 41.32% up since then. When we look at Transmedics Group Inc’s average trading volume, we note the 10-day average is 1.86 million shares, with the 3-month average coming to 1.40 million.

Analysts gave the Transmedics Group Inc (TMDX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended TMDX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Transmedics Group Inc’s EPS for the current quarter is expected to be 0.22.

Transmedics Group Inc (NASDAQ:TMDX) trade information

Instantly TMDX is in green as seen in intraday trades today. With action 12.16%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 22.70%, with the 5-day performance at 12.16% in the green. However, in the 30-day time frame, Transmedics Group Inc (NASDAQ:TMDX) is -26.54% down. Looking at the short shares, we see there were 8.43 million shares sold at short interest cover period of 4.06 days.

The consensus price target for the stock as assigned by Wall Street analysts is 135, meaning bulls need an upside of 28.26% from its recent market value. According to analyst projections, TMDX’s forecast low is 45 with 180 as the target high. To hit the forecast high, the stock’s price needs a -85.85% plunge from its current level, while the stock would need to tank 53.54% for it to hit the projected low.

Transmedics Group Inc (TMDX) estimates and forecasts

Data shows that the Transmedics Group Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -28.86% over the past 6 months, a 238.96% in annual growth rate that is considerably higher than the industry average of 15.90%. Year-over-year growth is forecast to reach 79.70% up from the last financial year.

Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 113.44M. 6 analysts are of the opinion that Transmedics Group Inc’s revenue for the current quarter will be 125.9M. The company’s revenue for the corresponding quarters a year ago was 81.17M and 96.85M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 39.70%. The estimates for the next quarter sales put growth at 30.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.36%. The 2024 estimates are for Transmedics Group Inc earnings to increase by 235.43%.

TMDX Dividends

Transmedics Group Inc is expected to release its next quarterly earnings report on 2025-Feb-24.

Transmedics Group Inc (NASDAQ:TMDX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 3.18% of Transmedics Group Inc shares while 106.95% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.46%. There are 106.95% institutions holding the Transmedics Group Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 13.7063% of the shares, roughly 4.49 million TMDX shares worth $676.31 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.0755% or 2.65 million shares worth $398.47 million as of 2024-06-30.